Platelet monoamine oxidase-A activity and aging: effect of carnosine

S Banerjee1, M K Poddar

  • 1Department of Biochemistry, University of Calcutta, 35, B.C. Road, Kolkata 700 019, India.

Insights

Carnosine supplementation can reverse age-related decline in platelet monoamine oxidase A (MAO-A) activity in rats. Higher carnosine doses restored enzyme function, suggesting potential therapeutic benefits for aging.

Area of Science:

  • Biochemistry
  • Gerontology
  • Pharmacology

Background:

  • Aging is associated with significant physiological changes, including alterations in enzyme activity.
  • Platelet mitochondrial monoamine oxidase A (MAO-A) activity, crucial for neurotransmitter metabolism, declines with age.
  • This age-induced inhibition of MAO-A is linked to reduced Vmax, impacting enzyme kinetics.

Purpose of the Study:

  • To investigate the effect of carnosine on age-related changes in platelet mitochondrial MAO-A activity.
  • To determine the dose-dependent efficacy of carnosine in modulating MAO-A activity in young and aged rats.

Main Methods:

  • Male Wistar rats of varying ages (young, 18, and 24 months) were used.
  • Administration of varying dosages of carnosine (0.5, 1.0, 2.0-2.5 μg/kg/day, intrathecally) for 21 consecutive days.
  • Measurement of platelet mitochondrial MAO-A activity and its Vmax.

Main Results:

  • Low-dose carnosine (0.5 μg/kg/day) had no significant effect on MAO-A activity in either young or aged rats.
  • Higher carnosine doses (2.0-2.5 μg/kg/day) significantly enhanced MAO-A activity in aged rats, reversing age-induced inhibition.
  • An intermediate dose (1.0 μg/kg/day) enhanced MAO-A activity specifically in aged rats.

Conclusions:

  • Carnosine effectively counteracts the age-related inhibition of mammalian blood platelet MAO-A activity.
  • Higher dosages of carnosine restore MAO-A activity to levels observed in younger individuals.
  • Carnosine demonstrates potential as a therapeutic agent to mitigate age-associated declines in MAO-A function.

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Mitochondria01:37

Mitochondria

Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
The Effect of Aging on Tissues01:19

The Effect of Aging on Tissues

Several body functions deteriorate with age. The external signs of aging are easily identifiable. For example, the skin becomes dry, less elastic, and thins out, forming wrinkles. The skin of the face begins to appear looser due to a decrease in the levels of elastic and collagen fibers in the connective tissue. Additionally, melanin production in the hair follicle decreases with age, resulting in gray hair. Moreover, the senses of sight and hearing decline, so glasses and hearing aids may...